Tara Bancroft
Stock Analyst at TD Cowen
(4.82)
# 483
Out of 5,032 analysts
297
Total ratings
49.8%
Success rate
25.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tara Bancroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBTX Nanobiotix | Reiterated: Buy | n/a | $25.59 | - | 4 | Sep 25, 2026 | |
| RCUS Arcus Biosciences | Initiated Coverage: Buy | n/a | $24.28 | - | 1 | Sep 16, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | n/a | $26.89 | - | 1 | Sep 9, 2026 | |
| EYPT EyePoint | Downgraded: Hold | $20 → $4 | $3.17 | +26.18% | 4 | Sep 2, 2026 | |
| CELC Celcuity | Reiterated: Buy | n/a | $71.25 | - | 14 | Aug 13, 2026 | |
| FATE Fate Therapeutics | Reiterated: Hold | n/a | $2.29 | - | 14 | Aug 13, 2026 | |
| MGNX MacroGenics | Reiterated: Hold | n/a | $3.64 | - | 15 | Aug 13, 2026 | |
| STRO Sutro Biopharma | Reiterated: Buy | n/a | $14.45 | - | 13 | Aug 12, 2026 | |
| TCRX TScan Therapeutics | Reiterated: Buy | n/a | $0.2754 | - | 12 | Aug 12, 2026 | |
| VALN Valneva SE | Initiated Coverage: Buy | $12 | $5.85 | +105.13% | 1 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.48 | - | 3 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.61 | - | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $1.21 | +147.93% | 20 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $66.70 | +12.44% | 16 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $155 | $138.69 | +11.76% | 17 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 → $60 | $41.43 | +44.82% | 24 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $24.36 | - | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $110 → $103 | $99.95 | +2.55% | 21 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $7.34 | +172.48% | 24 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $52.19 | +43.71% | 14 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.78 | - | 13 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $61.65 | - | 14 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $2.66 | - | 1 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $21.95 | - | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20.00 | $15.93 | +25.59% | 16 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.09 | n/a | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $4.60 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.57 | n/a | 2 | Jul 26, 2024 |
Nanobiotix
Sep 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.59
Upside: -
Arcus Biosciences
Sep 16, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $24.28
Upside: -
Faeth Therapeutics
Sep 9, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $26.89
Upside: -
EyePoint
Sep 2, 2026
Downgraded: Hold
Price Target: $20 → $4
Current: $3.17
Upside: +26.18%
Celcuity
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $71.25
Upside: -
Fate Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.29
Upside: -
MacroGenics
Aug 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.64
Upside: -
Sutro Biopharma
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.45
Upside: -
TScan Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.2754
Upside: -
Valneva SE
Aug 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $5.85
Upside: +105.13%
Aug 10, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.48
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.61
Upside: -
Aug 5, 2026
Rated: Buy
Price Target: $3
Current: $1.21
Upside: +147.93%
Aug 5, 2026
Reiterated: Buy
Price Target: $75
Current: $66.70
Upside: +12.44%
Aug 5, 2026
Reiterated: Buy
Price Target: $155
Current: $138.69
Upside: +11.76%
Aug 5, 2026
Rated: Buy
Price Target: $50 → $60
Current: $41.43
Upside: +44.82%
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $24.36
Upside: -
Aug 3, 2026
Downgraded: Hold
Price Target: $110 → $103
Current: $99.95
Upside: +2.55%
Aug 3, 2026
Reiterated: Buy
Price Target: $20
Current: $7.34
Upside: +172.48%
Aug 3, 2026
Reiterated: Buy
Price Target: $75
Current: $52.19
Upside: +43.71%
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.78
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $61.65
Upside: -
Jun 15, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $2.66
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.95
Upside: -
Feb 19, 2026
Reiterated: Buy
Price Target: $20.00
Current: $15.93
Upside: +25.59%
Mar 14, 2025
Rated: Hold
Price Target: n/a
Current: $1.09
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: n/a
Current: $4.60
Upside: n/a
Jul 26, 2024
Downgraded: Hold
Price Target: n/a
Current: $13.57
Upside: n/a